ANI Pharmaceuticals’ (ANIP) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reaffirmed their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report issued on Friday,Benzinga reports. The brokerage currently has a $124.00 price target on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings upgraded ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded down $1.71 during trading hours on Friday, hitting $82.07. 241,447 shares of the stock were exchanged, compared to its average volume of 305,538. The company’s fifty day simple moving average is $81.58 and its two-hundred day simple moving average is $79.51. The company has a market cap of $1.87 billion, a PE ratio of 20.78 and a beta of 0.43. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals has a 1-year low of $62.60 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The business had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same period in the previous year, the business earned $1.70 earnings per share. The company’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals will post 8.03 EPS for the current year.

Insider Activity

In other news, SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $79.21, for a total value of $36,357.39. Following the completion of the transaction, the senior vice president directly owned 38,271 shares in the company, valued at approximately $3,031,445.91. This represents a 1.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas Haughey sold 2,000 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total value of $161,760.00. Following the sale, the director owned 38,878 shares in the company, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 85,179 shares of company stock valued at $6,720,651. 8.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the period. Jane Street Group LLC bought a new stake in shares of ANI Pharmaceuticals in the first quarter worth $2,706,000. Finally, Norges Bank bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth $625,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.